IDEAYA Biosciences Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 IDEAYA Biosciences Inc 公司

IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).

IDEAYA Biosciences Inc简介



公司代码IDYA

公司名称IDEAYA Biosciences Inc

上市日期May 23, 2019

CEOHata (Yujiro S)

员工数量131

证券类型Ordinary Share

年结日May 23

公司地址7000 Shoreline Ct, Suite 350

城市SOUTH SAN FRANCISCO

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编94080

电话16504436209

网址https://www.ideayabio.com/

公司代码IDYA

上市日期May 23, 2019

CEOHata (Yujiro S)

IDEAYA Biosciences Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Yujiro S. Hata

President, Chief Executive Officer, Director

--

Mr. Andres Ruiz Briseno, CPA

Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations

--

Ms. Wendy L. Yarno

Independent Director

--

Mr. Scott W. Morrison, CPA

Independent Director

--

Dr. Terry J. Rosen, Ph.D.

Independent Chairman of the Board

--

Dr. Jeffrey L. (Jeff) Stein, Ph.D.

Independent Director

--

Dr. M. Garret Hampton, Ph.D.

Independent Director

--

Dr. Catherine J. Mackey, Ph.D.

Independent Director

--

Dr. Michael A. White, Ph.D.

Chief Scientific Officer

--

Dr. Darrin Beaupre, M.D., Ph.D.

Chief Medical Officer

--

名称

名称/职务

职务

持股

持股变动

Mr. Yujiro S. Hata

President, Chief Executive Officer, Director

--

Mr. Andres Ruiz Briseno, CPA

Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations

--

Ms. Wendy L. Yarno

Independent Director

--

Mr. Scott W. Morrison, CPA

Independent Director

--

Dr. Terry J. Rosen, Ph.D.

Independent Chairman of the Board

--

Dr. Jeffrey L. (Jeff) Stein, Ph.D.

Independent Director

--

收入明细

单位: USD更新时间: 1月6日周二

FY2024

FY2024Q4

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

业务USD

名称

营收

占比

WRN

7.00M

0.00%

MAT2A

0.00

0.00%

Pol Theta

0.00

0.00%

地区USD

名称

营收

占比

United States

7.00M

100.00%

业务

地区

业务USD

名称

营收

占比

WRN

7.00M

0.00%

MAT2A

0.00

0.00%

Pol Theta

0.00

0.00%

股东统计

更新时间: 2月7日周六

持股股东

股东类型

持股股东

占比

Fidelity Management & Research Company LLC

15.00%

Capital Research Global Investors

7.47%

Janus Henderson Investors

7.33%

BlackRock Institutional Trust Company, N.A.

7.23%

The Vanguard Group, Inc.

5.70%

其他

57.27%

持股股东

占比

Fidelity Management & Research Company LLC

15.00%

Capital Research Global Investors

7.47%

Janus Henderson Investors

7.33%

BlackRock Institutional Trust Company, N.A.

7.23%

The Vanguard Group, Inc.

5.70%

其他

57.27%

股东类型

持股股东

占比

Investment Advisor

49.40%

Investment Advisor/Hedge Fund

32.28%

Hedge Fund

19.91%

Research Firm

3.93%

Venture Capital

3.62%

Pension Fund

0.95%

Individual Investor

0.91%

Bank and Trust

0.45%

Insurance Company

0.07%

机构持股



更新时间: 1月1日周四

报告期

机构数

持股数

持股占比

持股变动

2025Q4

494

96.98M

110.62%

-16.62M

2025Q3

460

105.73M

120.62%

-11.57M

2025Q2

449

101.70M

116.06%

-6.32M

2025Q1

454

97.81M

111.68%

-11.15M

2024Q4

442

95.26M

108.96%

-7.87M

2024Q3

426

95.20M

112.79%

+2.56M

2024Q2

409

85.26M

112.59%

-3.91M

2024Q1

388

81.45M

108.91%

-1.44M

2023Q4

351

68.31M

105.94%

-512.62K

2023Q3

331

61.92M

105.66%

-3.64M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Fidelity Management & Research Company LLC

13.15M

15%

+9.25K

+0.07%

Sep 30, 2025

Capital Research Global Investors

6.55M

7.47%

--

Sep 30, 2025

Janus Henderson Investors

6.43M

7.33%

+222.10K

+3.58%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

6.34M

7.23%

-336.88K

-5.05%

Sep 30, 2025

The Vanguard Group, Inc.

4.90M

5.59%

-19.74K

-0.40%

Sep 30, 2025

Federated Hermes Global Investment Management Corp.

4.63M

5.28%

-1.42K

-0.03%

Sep 30, 2025

Point72 Asset Management, L.P.

3.82M

4.35%

-1.21M

-24.12%

Sep 30, 2025

Baker Bros. Advisors LP

3.28M

3.74%

+1.16M

+54.59%

Sep 30, 2025

State Street Investment Management (US)

3.24M

3.7%

-144.86K

-4.28%

Sep 30, 2025

Adage Capital Management, L.P.

2.90M

3.31%

+1.66M

+134.24%

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Tema Oncology ETF

3.49%

ALPS Medical Breakthroughs ETF

1.16%

Virtus LifeSci Biotech Clinical Trials ETF

0.97%

Invesco Dorsey Wright Healthcare Momentum ETF

0.83%

State Street SPDR S&P Biotech ETF

0.72%

First Trust Innovation Leaders ETF

0.7%

Direxion Daily S&P Biotech Bull 3X Shares

0.45%

ProShares Ultra Nasdaq Biotechnology

0.38%

Avantis US Small Cap Equity ETF

0.29%

Invesco Nasdaq Biotechnology ETF

0.27%

Tema Oncology ETF

占比3.49%

ALPS Medical Breakthroughs ETF

占比1.16%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.97%

Invesco Dorsey Wright Healthcare Momentum ETF

占比0.83%

State Street SPDR S&P Biotech ETF

占比0.72%

First Trust Innovation Leaders ETF

占比0.7%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.45%

ProShares Ultra Nasdaq Biotechnology

占比0.38%

Avantis US Small Cap Equity ETF

占比0.29%

Invesco Nasdaq Biotechnology ETF

占比0.27%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

暂无数据

公告日期

除权除息日

类型

比率

暂无数据